乙二胺四乙酸二胺 | 20824-56-0

• 物质功能分类: 有机原料 - 氨基化合物 - 无环单胺、多胺及其衍生物和盐
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 乙二胺四乙酸二胺
• 中文别名: 乙二胺四乙酸二铵；乙二胺四乙酸磷酸氢二铵盐水合物；EDTA二铵
• 英文名称: Diammonium ethylenediaminetetraacetate
• 英文别名: azane;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid
• CAS: 20824-56-0
• 化学式: C10H16N2O8.2H3N
• 分子量: 326.3
• InChiKey: KYQODXQIAJFKPH-UHFFFAOYSA-N

物化性质

• 熔点：
  215-217°C
• 密度：
  1.483[at 20℃]
• 溶解度：
  H2O: 0.1 M ， 20 °C, 澄清，无色
• LogP：
  -7.01 at 25℃
• 物理描述：
  Liquid

计算性质

• 辛醇/水分配系数(LogP)：
  -3.99
• 重原子数：
  22
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  163
• 氢给体数：
  4
• 氢受体数：
  10

安全信息

• TSCA：
  Yes
• 危险品标志：
  Xi
• 安全说明：
  S22,S24/25
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  29224985

制备方法与用途

用途

乙二胺四乙酸二钠是一种螯合剂。

反应信息

• 作为反应物：
  描述：

  双氧水 、 氯化钡 、 氨 、 盐酸 、 titanium(IV) isopropylate 、 乙二胺四乙酸二胺 生成 Barium titanate(IV)
  参考文献：
  名称：

  GHERARDI, P.;MATIJEVIC, E., HIGH. TECH CERAM.: PROC. WORLD CONGR. 6TH INT. MEET. MOD. CERAM. TECHNOL.+

  摘要：

  DOI：
• 作为产物：
  描述：

  ethanediyldiimino-tetra-acetic acid ; monomagnesium salt 、 氟化铵 生成 乙二胺四乙酸二胺
  参考文献：
  名称：

  FLIGIER, MIROSLAW

  摘要：

  DOI：

文献信息

• Imaging compounds, methods of making imaging compounds, methods of imaging, therapeutic compounds, methods of making therapeutic compounds, and methods of therapy
  申请人：Chen Xiaoyuan

  公开号：US20080267882A1

  公开（公告）日：2008-10-30

  Embodiments of the present disclosure provide for RGD compounds that include a multimeric RGD (arginine-glycine-aspartic acid (Arg-Gly-Asp)) peptide, methods of making the RGD compound, pharmaceutical compositions including RGD compound, methods of using the RGD compositions or the pharmaceutical compositions including RGD compositions, methods of diagnosing and/or targeting angiogenesis related disease and related biological events, kits for diagnosing and/or targeting angiogenesis related disease and related biological events, and the like. In addition, the present disclosure includes compositions used in and methods relating to non-invasive imaging (e.g., positron emission tomography (PET) imaging) of the RGD compounds in vivo.

  本公开的实施例提供了包括多聚体RGD（精氨酸-甘氨酸-天冬氨酸（Arg-Gly-Asp））肽的RGD化合物，制备RGD化合物的方法，包括RGD化合物的药物组合物，使用RGD组合物或包括RGD组合物的药物组合物的方法，诊断和/或靶向血管生成相关疾病和相关生物事件的方法，用于诊断和/或靶向血管生成相关疾病和相关生物事件的试剂盒等。此外，本公开还包括用于体内非侵入性成像（例如正电子发射断层扫描（PET）成像）的RGD化合物的成分和方法。
• SUBSTITUTED AMINOTETRALINES
  申请人：Firooznia Fariborz

  公开号：US20100041713A1

  公开（公告）日：2010-02-18

  The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein R 1 -R 4 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

  这项发明涉及式I的化合物： 及其药用可接受的盐和酯，其中R1-R4在详细说明和权利要求中有定义。此外，本发明涉及制造和使用式I的化合物的方法，以及含有这种化合物的药物组合物。式I的化合物是CRTH2受体的拮抗剂，可能在治疗与该受体相关的疾病和紊乱方面有用，如哮喘。
• [EN] COMPOUNDS<br/>[FR] COMPOSÉS
  申请人：UNIV OSLO

  公开号：WO2018033719A1

  公开（公告）日：2018-02-22

  The invention provides compounds for use in a method of treating and/or preventing a bacterial infection in a human or non-human mammal, said method comprising administration of said compound in combination with (either simultaneously, separately, or sequentially) a β-lactam antibiotic, wherein said compound has the general formula I: (I) (wherein: Q is a lipophilic, zinc chelating moiety which is selective for Zn2+ ions and which comprises at least one, preferably two or more (e.g 2, 3 or 4), optionally substituted, unsaturated heterocyclic rings, e.g. 5 or 6-membered heterocyclic rings (such rings preferably include at least one heteroatom selected from N, S and O, preferably N); wherein any optional substituents may be selected from C1-6 alkyl, C1-6 alkoxy, halogen, nitro, cyano, amine, and substituted amine; each L, which may be the same or different, is a covalent bond or a linker; each W, which may be the same or different, is a non-peptidic hydrophilic group which comprises one or more hydroxy groups; and x is an integer from 1 to 3) or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof.

  该发明提供了一种化合物，用于治疗和/或预防人类或非人哺乳动物体内的细菌感染，所述方法包括将该化合物与β-内酰胺类抗生素（可以同时、分开或顺序地）结合给药，其中所述化合物具有一般式I：（I）（其中：Q是一个亲脂性、选择性结合Zn2+离子的基团，包括至少一个，最好是两个或更多（例如2、3或4个），可选择地取代的不饱和杂环环，例如5或6元杂环环（这些环最好包括至少一个从N、S和O中选择的杂原子，最好是N）；其中任何可选择的取代基可以选择自C1-6烷基、C1-6烷氧基、卤素、硝基、氰基、胺和取代胺；每个L，可以相同也可以不同，是一个共价键或一个连接基；每个W，可以相同也可以不同，是一个非肽性亲水基团，包括一个或多个羟基；x是1到3之间的整数）或其立体异构体、药学上可接受的盐或前药。
• Compositions and Methods for Fermentation of Biomass
  申请人：Parekh Sarad

  公开号：US20100268000A1

  公开（公告）日：2010-10-21

  In one aspect, this invention relates to production of useful fermentation end-products from biomass through simultaneous hydrolysis and fermentation by a microorganism, such as Clostridium phytofermentans . The invention also relates to the development of a process for efficient pretreatment and conversion of lignocellulosic biomass to end-products with high conversion efficiency (yield). In another aspect, methods for producing a fermentation end-product by fermenting hexose (C6) and pentose (C5) sugars with a microorganism, such as Clostridium phytofermentans are disclosed herein.

  在一个方面，这项发明涉及通过微生物（如植物发酵槽菌）的同时水解和发酵，从生物质中生产有用的发酵终产物。该发明还涉及开发一种高效预处理和转化木质纤维素生物质为高转化效率（产率）的终产物的过程。在另一个方面，本文介绍了利用微生物（如植物发酵槽菌）发酵己糖（C6）和戊糖（C5）糖产生发酵终产物的方法。
• [EN] A PROCESS FOR THE PRODUCTION OF ALKYLENE OXIDE USING A GAS-PHASE PROMOTER SYSTEM<br/>[FR] PROCEDE DE FABRICATION D'OXYDE D'ALKYLENE AU MOYEN D'UN SYSTEME PROMOTEUR EN PHASE GAZEUSE
  申请人：UNION CARBIDE CHEM PLASTIC

  公开号：WO2005035513A1

  公开（公告）日：2005-04-21

  An improved process for the manufacture of ethylene oxide through the epoxidation of ethylene using a catalyst comprising silver and at least one efficiency-enhancing salt of a member of a redox-half reaction pair. Added to the epoxidation reaction is a two-component gas-phase promoter system comprising a chlorine-containing component (for example ethyl chloride, methyl chloride, vinyl chloride and ethylene dichloride), and a nitrogen-containing component of nitric oxide and other compounds capable of generating under reaction conditions at least one gaseous efficiency-enhancing member of a redox-half reaction pair comprising NO, NO2, N2O3 or N2O4. The amount of each component of said gaseous promoter is adjusted to maintain the ration of N* to Z* less than or equal to 1 wherein, N* is the nitric oxide equivalent in ppmv, ranging from 1 to 20 ppmv and Z* =ethyl chloride equivalent (ppmv) * 100 percent / ethane equivalent (mol percent) * 100 ranging from 5 to 40 ppmv.

  通过使用包含银和至少一种效率增强盐的催化剂，在乙烯环氧化反应中制备环氧乙烷的改进工艺。向环氧化反应中添加了一个两组分气相促进剂系统，包括一个含氯组分（例如氯乙烷、氯甲烷、氯乙烯和二氯乙烷），以及一个含氮组分，如一氧化氮和其他在反应条件下能够生成至少一个气态效率增强成员的化合物，其中包括NO、NO2、N2O3或N2O4。调整所述气态促进剂的每个组分的量，以保持N*与Z*的比例小于或等于1，其中，N*是以ppmv为单位的一氧化氮当量，范围从1到20 ppmv，而Z* = 乙烯氯化物当量（ppmv）* 100％/乙烷当量（摩尔百分比）* 100，范围从5到40 ppmv。

表征谱图